AESKU DIAGNOSTICS
- Shared products
- ANTIBODY ANTI-EXTRACTABLE NUCLEAR ANTIGENS (ENA), ANTICYTOPLASMIC ANTIBODY, ANTINUCLEAR ANTIBODY (ANA), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS II
- Shared products
- ANTIBODY ANTI-EXTRACTABLE NUCLEAR ANTIGENS (ENA), ANTICYTOPLASMIC ANTIBODY, ANTINUCLEAR ANTIBODY (ANA), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS II
- Shared products
- ANTIBODY ANTI-EXTRACTABLE NUCLEAR ANTIGENS (ENA), ANTICYTOPLASMIC ANTIBODY, ANTINUCLEAR ANTIBODY (ANA), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS II
- Shared products
- ANTIBODY ANTI-EXTRACTABLE NUCLEAR ANTIGENS (ENA), ANTICYTOPLASMIC ANTIBODY, ANTINUCLEAR ANTIBODY (ANA), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS II
- Shared products
- ANTIBODY ANTI-EXTRACTABLE NUCLEAR ANTIGENS (ENA), ANTICYTOPLASMIC ANTIBODY, ANTINUCLEAR ANTIBODY (ANA), COMBINED PARAMETERS IN THE SAME PRODUCT - CLASS II
Explore comprehensive manufacturer profile for AESKU DIAGNOSTICS based in Germany through Pure Global AI's free Brazil medical device database. This manufacturer has 11 products registered with ANVISA across 4 unique technical categories. Their regulatory history spans from Jan 10, 2011 to Jan 08, 2018.
This page provides detailed insights including 5 recent product registrations including ANTICYTOPLASMIC ANTIBODY, 4 most popular products with ANTIBODY ANTI-EXTRACTABLE NUCLEAR ANTIGENS (ENA) having 6 registrations, 2 registration holders including MEDIVAX INDÚSTRIA E COMÉRCIO LTDA, and 5 key competitors with ORGENTEC DIAGNOSTIKA GMBH sharing 4 products. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, enabling global MedTech companies to analyze market dynamics and identify opportunities.